Prophylactic Use of Voriconazole for Invasive Fungal Infection in Children and Adolescents with Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
New Option Soon for Some European Patients With Leukemia New Option Soon for Some European Patients With Leukemia
Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 20, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists. Â (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to clinical stage with lead Acute Myeloid Leukemia ("AML") compound BTX-A51
CHAPPAQUA, N.Y., Sept. 18, 2019... Biopharmaceuticals, Oncology, Personnel BioTheryX, Protein Homeostatic Modulators (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2019 Category: Pharmaceuticals Source Type: news
Many Older Patients With AML Not Receiving Active Treatment
WEDNESDAY, Sept. 18, 2019 -- Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in Cancer.
Amer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 18, 2019 Category: Pharmaceuticals Source Type: news
Gilteritinib Changes AML Landscape
The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Washington University gets $15M grant to study leukemia
Washington University investigators at Siteman Cancer Center at Barnes-Jewish Hospital and the School of Medicine have been awarded a $15 million grant to study the genetic changes that drive acute myeloid leukemia (AML), a deadly blood cancer.
Findings from their studies may help develop more effective therapies for patients, officials said. The grant is funded by the National Cancer Institute of the National Institutes of Health.
Earlier funding for AML and a gift from Alvin Siteman allowed… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 22, 2019 Category: Biotechnology Authors: Veneta Rizvic Source Type: news
Gal9/TIM-3 Expression Levels Affects Chemotherapy in Leukemia Patients
A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 22, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
TP53, which encodes the tumor suppressor p53, is the most frequently mutated gene in human cancer. The selective pressures shaping its mutational spectrum, dominated by missense mutations, are enigmatic, and neomorphic gain-of-function (GOF) activities have been implicated. We used CRISPR-Cas9 to generate isogenic human leukemia cell lines of the most common TP53 missense mutations. Functional, DNA-binding, and transcriptional analyses revealed loss of function but no GOF effects. Comprehensive mutational scanning of p53 single–amino acid variants demonstrated that missense variants in the DNA-binding domain exert a ...
Source: ScienceNOW - August 7, 2019 Category: Science Authors: Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., Kurppa, K. J., Yang, X., Milenkowic, K., Piccioni, F., Root, D. E., Rücker, F. G., Flamand, Y., Neuberg, D., Li Tags: Medicine, Diseases reports Source Type: news
Mutation of KDM6A Gene in Relapsed Acute Myeloid Leukemia
With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments. A new study published in Leukemia is suggesting that the loss of KDM6A in patients with acute myeloid leukemia (AML) may provide cells with a selective advantage during chemotherapy, leading to the development of clones with KDM6A mutations or reduced KDM6A expression at the time of relapse. A majority of patients with AML relapse due to intrinsic or acquired drug resistance. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
The Role of 4-GES Gene Expression Signatures in AML Prognostics
A new suggests that the gene expression signature 4-GES, which consists of four genes (SOCS2, IL2RA, NPDC1, PHGDH), may be an independent prognostic factor in acute myeloid leukemia (AML). Writing in Scientific Reports, researchers report 4-GES is a highly significant independent prognostic parameter throughout several independent AML cohorts and it has a major advantage over previously published signatures because it is composed of only four genes. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Sorafenib Impacted Survival Rates in Acute Myeloid Leukemia
The addition of sorafenib to intensive chemotherapy had a significant impact on the survival rate of patients with FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - July 17, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Acute Leukemia | Medscape Acute Leukemia | Medscape
Acute forms of leukemia include acute myeloid leukemia and acute lymphoblastic leukemia, also known as lymphoblastic lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
Aspergillus nidulans appendicitis in a paediatric patient with acute myeloid leukaemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 1, 2019 Category: Respiratory Medicine Authors: pChrisopoulos Source Type: news
